DIAPREPP
"DIAbetes type 1 PRediction, Early Pathogenesis and Prevention"
| Coordinatore | TECHNISCHE UNIVERSITAET DRESDEN
Organization address
address: HELMHOLTZSTRASSE 10 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.diaprepp.eu/ |
| Totale costo | 7˙794˙397 € |
| EC contributo | 5˙999˙200 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-FP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-04-01 - 2011-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TECHNISCHE UNIVERSITAET DRESDEN
Organization address
address: HELMHOLTZSTRASSE 10 contact info |
DE (DRESDEN) | coordinator | 0.00 |
| 2 |
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR
Organization address
address: Via Olgettina 60 contact info |
IT (MILANO) | participant | 0.00 |
| 3 |
FORSCHERGRUPPE DIABETES E. V. - INSTITUT FUER DIABETESFORSCHUNG
Organization address
address: INGOLSTADTER LANDSTRASSE 1 contact info |
DE (OBERSCHLEISSHEIM NEUHERBERG) | participant | 0.00 |
| 4 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 0.00 |
| 5 |
LUNDS UNIVERSITET
Organization address
address: Paradisgatan 5c contact info |
SE (LUND) | participant | 0.00 |
| 6 |
RSR LIMITED
Organization address
address: "Avenue Park, Pantwyn" contact info |
UK (CARDIFF) | participant | 0.00 |
| 7 |
TEKNOLOGIAN TUTKIMUSKESKUS VTT
Organization address
address: TEKNIIKANTIE 4 A contact info |
FI (ESPOO) | participant | 0.00 |
| 8 |
TERVEYDEN JA HYVINVOINNIN LAITOS
Organization address
address: MANNERHEIMINTIE 166 contact info |
FI (HELSINKI) | participant | 0.00 |
| 9 |
UNIVERSITAT DE BARCELONA
Organization address
address: GRAN VIA DE LES CORTS CATALANES 585 contact info |
ES (BARCELONA) | participant | 0.00 |
| 10 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 0.00 |
| 11 |
VARSINAIS-SUOMEN SAIRAANHOITOPIIRIN KUNTAYHTYMA
Organization address
address: KIINAMYLLYNKATU 4-8 contact info |
FI (TURKU) | participant | 0.00 |
| 12 |
ZORA BIOSCIENCES LTD
Organization address
address: Biologinkuja 1 contact info |
FI (ESPOO) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The earliest currently identifiable process in the pathogenesis of type 1 diabetes (T1D) is the development of autoimmunity to islet beta cells in the form of autoantibodies. Hindering attempts to prevent autoimmune T1D, the aetiology and pathogenesis of the islet auto-immunization, including whether it is preceded by metabolic abnormalities and cell-mediated autoimmunity, is still poorly understood. To overcome this, DIAPREPP will focus on the early auto-immunization against islet antigens, in particular to disclose events preceding current autoantibody markers. The concept is that events prior to auto-immunization govern the likelihood and ‘signature’ of immunization, which in turn determines progression to disease. The overall objective is to determine mechanisms of islet autoantigen immunization. In a truly collaborative manner, and through five S/T workpackages plus three dedicated to dissemination, training, and management, DIAPREPP will 1. provide a unique set of clinical material that includes a case-control cohort representative of the world’s largest studies of pre-T1D, with follow-up and samples from birth, and pancreatic islets and lymph nodes from patients; 2. investigate the effects of environmental exposure to infections on islet cells and immune cells; 3. perform extensive metabolomic analysis of pre-autoimmune samples and in relevant animal models to test mechanistic hypotheses of auto-immunization; 4. carry out detailed analyses of early autoimmune responses with a special focus on autoreactive CD8 T cells; and 5. apply findings to ongoing prevention studies. The expected impact of DIAPREPP is new fundamental knowledge regarding how 1. immunization against islet autoantigens can occur; 2. signs of self-immunization can be exploited for prediction and monitoring of disease; and 3. the immunization or its progression to islet beta cell destruction and T1D development can be prevented.'
Introduzione (Teaser)
Understanding the causes of type1 diabetes (T1D) and finding early disease markers seem the only way forward to reduce disease incidence. Based on this, the DIAPREPP consortium set out to identify and exploit early events in the development of autoimmunity against islet beta antigens in a large cohort of children.